RedHill Biopharma Ltd (RDHL) has released an update.
RedHill Biopharma Ltd. has enrolled the first patient in a U.S. Department of Defense-funded COVID-19 study, set to complete by the end of 2024. The study evaluates RHB-107, a novel oral antiviral expected to work against various viral strains due to its host-directed mechanism. This comes on the heels of RHB-107 showing promising results in reducing hospitalizations and symptoms in a previous U.S. Phase 2 trial.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
